Protalix BioTherapeutics Inc Overview
Pro stress-test →Protalix BioTherapeutics is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs. The company has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. In Q1 2026, Protalix generated $7.4 million from product sales and $26.3 million from license/R&D activities, achieving net income of $18.3 million.
Strategic Profile
Pro stress-test →Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio, which was approved by both the FDA and the European Medicines Agency in May 2023. The company received a $25.0 million milestone from Chiesi in (March 2026) following European Commission approval of a 2mg/kg every-4-weeks Elfabrio dosing regimen for adults with Fabry disease. The development pipeline includes PRX-115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout treatment, and PRX-119, a plant cell-expressed long-acting DNase I for NETs-related diseases.
Competitive Landscape
Pro stress-test →Protalix operates in rare disease enzyme replacement therapy and specialized protein therapeutics. Key competitors include Sanofi (Fabrazyme, a competing Fabry disease treatment), Endo Pharmaceuticals (enzyme replacement therapies), and Amgen (broader rare disease portfolio). Protalix differentiates through its plant cell-based manufacturing platform (ProCellEx) and focused partnerships with established pharma companies like Chiesi and Pfizer.
Industry Context
Protalix BioTherapeutics Inc operates in Rare disease enzyme replacement therapies.
Key facts
Founded: 1993 · Headquarters: Karmiel, Israel · Revenue: $78–$83M (2026 guidance) · Market cap: $185M (as of June 25, 2026)